Emergent BioSolutions (EBS) Misses Q1 EPS by 1c, Reaffirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.19 -0.16%
EPS Growth %: -138.7%
Financial Fact:
Interest income: 358K
Today's EPS Names:
SICP, MNSB, CFFI, More
EPS Growth %: -138.7%
Financial Fact:
Interest income: 358K
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.29, $0.01 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $116.17 million.
Emergent BioSolutions reaffirmed guidance.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deckers Brands (DECK) Tops Q2 EPS by 24c; raises guidance
- Pool Corp. (POOL) Tops Q3 EPS by 4c; offers guidance
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
